Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641038 | 0.92 | MAPT (0.61) | MAPTMAPK1DDB1CRBNPDGFRB | |
| SCHEMBL26640184 | 0.91 | MAPT (0.60) | MAPTMAPK1DDB1CRBNPDGFRB | |
| SCHEMBL26640288 | 0.91 | MAPT (0.55) | MAPTGPR119MAPK1DDB1CRBN | |
| SCHEMBL30648780 | 0.91 | MAPT (0.55) | MAPTGPR119MAPK1DDB1CRBN | |
| SCHEMBL26640119 | 0.90 | MAPT (0.61) | MAPTMAPK1DDB1CRBNPDGFRB | |
| SCHEMBL26640800 | 0.90 | MAPT (0.58) | MAPTGPR119MAPK1DDB1CRBN | |
| SCHEMBL26640544 | 0.89 | MAPT (0.67) | MAPTMAPK1DDB1CRBNPDGFRB | |
| SCHEMBL26640688 | 0.89 | MAPT (0.66) | MAPTMAPK1DDB1CRBNPDGFRB | |
| SCHEMBL26640686 | 0.88 | MAPT (0.57) | MAPTGPR119MAPK1DDB1CRBN | |
| SCHEMBL26640306 | 0.88 | MAPT (0.65) | MAPTMAPK1DDB1CRBNPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | MAPT 3283/4885GPR119 1838/4885MAPK1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.